The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Open accessAbstract
Antisense 2'-O-methylribooligonucleotides were targeted against specific sequence elements in mutated human beta-globin pre-mRNAs to restore correct splicing of these RNAs in vitro. The following mutations of the beta-globin gene, A-->G at nt 110 of the first intron (beta 110), T-->G at nt 705 and C-->T at nt 654 of the second intron (IVS2(705) and IVS2(654), respectively), which led to aberrant splicing of the corresponding pre-mRNAs, were previously identified as the underlying causes of beta-thalassemia. Aberrant splicing of beta 110 pre-mRNA was efficiently reversed by an oligonucleotide targeted against the branch point sequence in the first intron of the pre-mRNA but not by an oligonucleotide targeted against the aberrant 3' splice site. In both IVS2(705) and IVS2(654) pre-mRNAs, correct splicing was restored by oligonucleotides targeted against the aberrant 5' splice sites created by the mutations in the second intron or against a cryptic 3' splice site located upstream and activated in the mutated background. These experiments represent an approach in which antisense oligonucleotides are used to restore the function of a defective gene and not, as usual, to down-regulate the expression of an undesirable gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[19] Rapid and efficient site-specific mutagenesis without phenotypic selection
Kunkel, T. A., Roberts, J. D., & Zakour, R. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54085-x · Cited by 5,261
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Krawczak, M., Reiss, J., & Cooper, D. (1992) · Human Genetics · doi:10.1007/bf00210743 · Cited by 1,324
Normal and mutant human β-globin pre-mRNAs are faithfully and efficiently spliced in vitro
Krainer, A. R., Maniatis, T., Ruskin, B., & Green, M. R. (1984) · Cell · doi:10.1016/0092-8674(84)90049-7 · Cited by 652
Alternative splicing and genomic structure of the Wilms tumor gene WT1.
Haber, D. A., Sohn, R. L., Buckler, A. J., Pelletier, J., Call, K. M., & Housman, D. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9618 · Cited by 620
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett, C. F., Chiang, M. Y., Chan, H., Shoemaker, J. E., & Mirabelli, C. K. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09229-6 · Cited by 612
Recognition of cap structure in splicing in vitro of mRNA precursors
Konarska, M. M., Padgett, R. A., & Sharp, P. A. (1984) · Cell · doi:10.1016/0092-8674(84)90268-x · Cited by 568
Antisense and Antigene Properties of Peptide Nucleic Acids
Hanvey, J. C., Peffer, N. J., Bisi, J. E., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) · Science · doi:10.1126/science.1279811 · Cited by 533
The spectrum of cystic fibrosis mutations
Tsui, L.-C. (1992) · Trends in Genetics · doi:10.1016/0168-9525(92)90301-j · Cited by 404
Intron sequences involved in lariat formation during pre-mRNA splicing
Reed, R., & Maniatis, T. (1985) · Cell · doi:10.1016/0092-8674(85)90064-9 · Cited by 383
Cited by
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Self-citationCooper, T. A., Wan, L., & Dreyfuss, G. (2009) · Cell · doi:10.1016/j.cell.2009.02.011 · Cited by 1,159
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Mechanisms of Cellular Uptake of Cell-Penetrating Peptides
Madani, F., Lindberg, S., Langel, Ü., Futaki, S., & Gräslund, A. (2011) · Journal of Biophysics · doi:10.1155/2011/414729 · Cited by 984
Cell‐penetrating peptides: 20 years later, where do we stand?
Bechara, C., & Sagan, S. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.031 · Cited by 857
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Morpholino antisense oligomers: the case for an RNase H-independent structural type
Summerton, J. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00150-5 · Cited by 664
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Nonsense-mediated decay approaches the clinic
Holbrook, J. A., Neu-Yilik, G., Hentze, M. W., & Kulozik, A. E. (2004) · Nature Genetics · doi:10.1038/ng1403 · Cited by 596
Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 574
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417
Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406700102 · Cited by 402
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S.-A., Fletcher, S., Partridge, T. A., & Wilton, S. D. (2003) · Nature Medicine · doi:10.1038/nm897 · Cited by 398
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Molecular mechanisms of action of antisense drugs
Crooke, S. T. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00148-7 · Cited by 358
Manoharan, M. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00138-4 · Cited by 348
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Lessons from non-canonical splicing
Sibley, C. R., Blazquez, L., & Ule, J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.46 · Cited by 316
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
Oligonucleotide Therapies: The Past and the Present
Lundin, K. E., Gissberg, O., & Smith, C. I. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.070 · Cited by 267
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y.-K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 264
Wheeler, T. M., Lueck, J. D., Swanson, M. S., Dirksen, R. T., & Thornton, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33355 · Cited by 256
Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C., & Dickson, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1083 · Cited by 255
Antisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“There have now been several studies showing that ASOs have the ability to bind pre-mRNA structure and directly modulate splicing, both in vitro and in vivo, by masking splicing enhancers and repressor sequences, skipping exons, and/or forcing inclusion of otherwise alternatively spliced exons [6, 34–39].”
BackgroundAntisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
“The best characterized examples of non-degradative mechanisms are ASOs that modulate pre-mRNA splicing to promote exclusion or inclusion of exons (20).”
Background
Metadata
- Authors
- Dominski, Z., & Kole, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-09-15
- Volume
- 90
- Issue
- 18
- Pages
- 8673-8677
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2040743013
- Cited by
- 426
- References
- 27
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.